ABOUT US
What We Do
Discovery Chemistry
One of the largest and most experienced chemistry discovery organizations having designed and synthesized millions of molecules for hundreds of global organizations
Biology and Pharmacology
Serving key bio-therapeutic areas, including oncology, cell biology, immunology, inflammation, and neuroscience, and providing assays and disease models to drive discovery
DMPK and Exploratory Tox
A science-based culture executing DMPK and tox studies and integrating quality data into drug discovery programs and supporting regulatory filings worldwide
Discovery Biologics
A comprehensive offering for monoclonal antibodies and recombinant proteins from conceptual design to IND filing: discover, engineer, express, purify, and analyze
Biologics CMC/CDMO
Experts at seamlessly transitioning biologics from discovery to CMC development and onto manufacturing to meet mAb production demands for clinical and commercial launch
Dedicated to Scientific Excellence
We are ChemPartner, a life science CRO/CDMO and experts in innovative pharmaceutical research with a global reach.
Our mission is to provide the biopharmaceutical industry with the highest quality R&D services in a timely and cost-effective manner.
Connect With Us
Join us on social media, see our latest news and publications, find us at an upcoming event, or access our large catalog of scientific resources.
LATEST NEWS
Latest News
San Diego, April 5-9, 2014, ChemPartner attended AACR.
The American Association for Cancer Research 2016 Annual Meeting，as one of the most important International tumor conference, was held in New Orleans on Apr 16th -20th .The topic was “Delivering Cures Through Cancer Science”. It is reported that more than 6000...
ChemPartner at the 3rd PEGS CHINA
The third Protein & Antibody Engineering and Development Summit (PEGS CHINA) sponsored by CHI (Cambridge Healthtech Institute) was held in Shanghai Pudong Grand Hyatt Hotel on Apr 5th, 2016. More than 200 participants from China, the United States, Europe and...
Blend Therapeutics Secures $38 Million in Series C Financing and Changes Name to Tarveda Therapeutics
On January 27, 2016, Tarveda Therapeutics, INC. has secured $38 million in Series C Financing co-led by new investor Novo A/S and existing investor NEA (New Enterprise Associates). Meanwhile, Tarveda also announced to change the former brand “Blend Therapeutic” to...
Headquarters
1F & 3F, Block A
2829 JinKe Road
Zhangjiang Hi-Tech Park
PuDong New Area
Shanghai China, 201203
Contact Us
China: +86 21 5132 0088
US: +1 650 419 9974
Europe: +45 4586 9000